Skip to main content
Erschienen in: Obesity Surgery 4/2010

01.04.2010 | Clinical Research

Chronic Increase of Bone Turnover Markers After Biliopancreatic Diversion is Related to Secondary Hyperparathyroidism and Weight Loss. Relation with Bone Mineral Density

verfasst von: José Antonio Balsa, José I. Botella-Carretero, Roberto Peromingo, Carmen Caballero, Teresa Muñoz-Malo, Juan J. Villafruela, Francisco Arrieta, Isabel Zamarrón, Clotilde Vázquez

Erschienen in: Obesity Surgery | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Biliopancreatic diversion (BPD) is the most effective bariatric procedure. Around 70% of these patients have secondary hyperparathyroidism (SH) in the long term as a consequence of calcium and vitamin D malabsorption. This work was aimed to study the influence of SH on bone turnover and its relationship with bone mineral density (BMD).

Methods

Bone turnover markers were determined in 63 BPD patients and 34 morbidly obese controls. In the BPD group, we also studied the influence of age, loss of weight, common channel length, PTH, vitamin D, and serum calcium on bone turnover as well as its relation with BMD.

Results

BPD patients showed significantly higher PTH, osteocalcin, and β-CTx levels than controls. In the multivariate regression analysis, only PTH (β = 0.42; P = 0.0002), menopausal status (β = 0.31; P = 0.007) and the percentage of lost BMI (β = −0.24; P = 0.03) significantly predicted the osteocalcin level (R 2 = 0.33; F = 9.56; P < 0.0001). Similarly, only PTH (β = 0.39; P = 0.0005), menopausal status (β = 0.37; P = 0.001) and the percentage of lost BMI (β = −0.23; P = 0.04) significantly predicted the β-CTx level (R 2 = 0.33; F = 9.82; P < 0.0001). Osteocalcin and β-CTx levels correlated negatively with BMD at lumbar spine (r = −0.38, P = 0.002 and r = −0.30, P = 0.02, respectively).

Conclusions

Chronic SH and the loss of weight determine a high rate of bone turnover that is associated with decreasing BMD in BPD patients.
Literatur
1.
Zurück zum Zitat Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg. 1998;22:936–46.CrossRefPubMed Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg. 1998;22:936–46.CrossRefPubMed
2.
Zurück zum Zitat Balsa JA, Botella-Carretero JI, Peromingo R, et al. Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Invest. 2008;31:845–50.PubMed Balsa JA, Botella-Carretero JI, Peromingo R, et al. Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Invest. 2008;31:845–50.PubMed
3.
Zurück zum Zitat Newbury L, Dolan K, Hatzifotis M, et al. Depletion and elevated parathyroid hormone following biliopancreatic diversion. Obes Surg. 2003;13:893–5.CrossRefPubMed Newbury L, Dolan K, Hatzifotis M, et al. Depletion and elevated parathyroid hormone following biliopancreatic diversion. Obes Surg. 2003;13:893–5.CrossRefPubMed
4.
Zurück zum Zitat Pugnale N, Giusti V, Suter M, et al. Bone metabolism and risk of secondary hyperparathyroidism 12 months after gastric banding in obese pre-menopausal women. Int J Obes Relat Metab Disord. 2003;27:110–6.CrossRefPubMed Pugnale N, Giusti V, Suter M, et al. Bone metabolism and risk of secondary hyperparathyroidism 12 months after gastric banding in obese pre-menopausal women. Int J Obes Relat Metab Disord. 2003;27:110–6.CrossRefPubMed
5.
Zurück zum Zitat Guney E, Kisakol G, Ozgen G, et al. Effect of weight loss on bone metabolism: comparison of vertical banded gastroplasty and medical intervention. Obes Surg. 2003;13:383–8.CrossRefPubMed Guney E, Kisakol G, Ozgen G, et al. Effect of weight loss on bone metabolism: comparison of vertical banded gastroplasty and medical intervention. Obes Surg. 2003;13:383–8.CrossRefPubMed
6.
Zurück zum Zitat Coates PS, Fernstrom JD, Fernstrom MH, et al. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab. 2004;89:1061–5.CrossRefPubMed Coates PS, Fernstrom JD, Fernstrom MH, et al. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab. 2004;89:1061–5.CrossRefPubMed
7.
8.
Zurück zum Zitat Gamero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int. 1996;52:S2–9. Gamero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int. 1996;52:S2–9.
9.
Zurück zum Zitat Taylor AK, Lueken SA, Libanati C, et al. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am. 1994;20:589–607.PubMed Taylor AK, Lueken SA, Libanati C, et al. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am. 1994;20:589–607.PubMed
10.
Zurück zum Zitat De Leo V, Ditto A, la Marca A, et al. Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif Tissue Int. 2000;66:263–7.CrossRefPubMed De Leo V, Ditto A, la Marca A, et al. Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif Tissue Int. 2000;66:263–7.CrossRefPubMed
11.
Zurück zum Zitat Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–41.CrossRefPubMed Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–41.CrossRefPubMed
12.
Zurück zum Zitat Duda RJ Jr, O’Brien JF, Katzmann JA, et al. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab. 1988;66:951–7.CrossRefPubMed Duda RJ Jr, O’Brien JF, Katzmann JA, et al. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab. 1988;66:951–7.CrossRefPubMed
13.
Zurück zum Zitat Deftos LJ, Parthemore JG, Price PA. Changes in plasma bone GLA protein during treatment of bone disease. Calcif Tissue Int. 1982;34:121–4.CrossRefPubMed Deftos LJ, Parthemore JG, Price PA. Changes in plasma bone GLA protein during treatment of bone disease. Calcif Tissue Int. 1982;34:121–4.CrossRefPubMed
14.
Zurück zum Zitat Brown JP, Delmas PD, Malaval L, et al. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984;1:1091–3.CrossRefPubMed Brown JP, Delmas PD, Malaval L, et al. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984;1:1091–3.CrossRefPubMed
15.
Zurück zum Zitat Okabe R, Nakatsuka K, Inaba M, et al. Clinical evaluation of the Elecsys β-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem. 2001;47:1410–4.PubMed Okabe R, Nakatsuka K, Inaba M, et al. Clinical evaluation of the Elecsys β-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem. 2001;47:1410–4.PubMed
16.
Zurück zum Zitat Fledelius C, Johnsen AH, Cloos PA, et al. Characterization of urinary degradation products derived from type I collagen. Identification of a β-isomerized Asp-Gly sequence within the C-terminal telopeptide (α1) region. J Biol Chem. 1997;272:9755–63.CrossRefPubMed Fledelius C, Johnsen AH, Cloos PA, et al. Characterization of urinary degradation products derived from type I collagen. Identification of a β-isomerized Asp-Gly sequence within the C-terminal telopeptide (α1) region. J Biol Chem. 1997;272:9755–63.CrossRefPubMed
17.
Zurück zum Zitat Okabe R, Inaba1 M, Nakatsuka K, et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab. 2004;22:127–31.CrossRefPubMed Okabe R, Inaba1 M, Nakatsuka K, et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab. 2004;22:127–31.CrossRefPubMed
18.
Zurück zum Zitat Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998;44:2281–9.PubMed Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998;44:2281–9.PubMed
19.
Zurück zum Zitat Slater GH, Ren CJ, Siegel N, et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastrointest Surg. 2004;8:48–55.CrossRefPubMed Slater GH, Ren CJ, Siegel N, et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastrointest Surg. 2004;8:48–55.CrossRefPubMed
20.
Zurück zum Zitat Fleischer J, Stein EM, Bessler M, et al. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab. 2008;93:3735–40.CrossRefPubMed Fleischer J, Stein EM, Bessler M, et al. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab. 2008;93:3735–40.CrossRefPubMed
21.
Zurück zum Zitat Moreiro J, Ruiz O, Perez G, et al. Parathyroid hormone and bone marker levels in patients with morbid obesity before and after biliopancreatic diversion. Obes Surg. 2007;17:348–54.CrossRefPubMed Moreiro J, Ruiz O, Perez G, et al. Parathyroid hormone and bone marker levels in patients with morbid obesity before and after biliopancreatic diversion. Obes Surg. 2007;17:348–54.CrossRefPubMed
22.
Zurück zum Zitat Chapin BL, LeMar HJJ, Knodel DH, et al. Secondary hyperparathyroidism following biliopancreatic diversion. Arch Surg. 1996;131:1048–52.PubMed Chapin BL, LeMar HJJ, Knodel DH, et al. Secondary hyperparathyroidism following biliopancreatic diversion. Arch Surg. 1996;131:1048–52.PubMed
23.
Zurück zum Zitat Nieves JW. Osteoporosis: the role of micronutrients. Am J Clin Nutr. 2005;81:1232S–9S.PubMed Nieves JW. Osteoporosis: the role of micronutrients. Am J Clin Nutr. 2005;81:1232S–9S.PubMed
24.
Zurück zum Zitat Rosen C, Chesnut CH 3rd, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 1997;82:1904–10.CrossRefPubMed Rosen C, Chesnut CH 3rd, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 1997;82:1904–10.CrossRefPubMed
25.
Zurück zum Zitat Dresner-Pollak R, Parker RA, Poku M, et al. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int. 1996;59:328–33.CrossRefPubMed Dresner-Pollak R, Parker RA, Poku M, et al. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int. 1996;59:328–33.CrossRefPubMed
26.
Zurück zum Zitat Reeve J, Pearson J, Mitchell A, et al. Evolution of spinal bone loss and biochemical markers of bone remodelling after menopause in normal women. Calcif Tissue Int. 1995;57:105–10.CrossRefPubMed Reeve J, Pearson J, Mitchell A, et al. Evolution of spinal bone loss and biochemical markers of bone remodelling after menopause in normal women. Calcif Tissue Int. 1995;57:105–10.CrossRefPubMed
27.
Zurück zum Zitat Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res. 1996;13:297–302.CrossRef Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res. 1996;13:297–302.CrossRef
28.
Zurück zum Zitat Riggs BL, Melton LJ III, O’Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone. 1996;18:S197–201.CrossRef Riggs BL, Melton LJ III, O’Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone. 1996;18:S197–201.CrossRef
29.
Zurück zum Zitat Marceau P, Biron S, Lebel S, et al. Does bone change after biliopancreatic diversion? J Gastrointest Surg. 2002;6:690–8.CrossRefPubMed Marceau P, Biron S, Lebel S, et al. Does bone change after biliopancreatic diversion? J Gastrointest Surg. 2002;6:690–8.CrossRefPubMed
Metadaten
Titel
Chronic Increase of Bone Turnover Markers After Biliopancreatic Diversion is Related to Secondary Hyperparathyroidism and Weight Loss. Relation with Bone Mineral Density
verfasst von
José Antonio Balsa
José I. Botella-Carretero
Roberto Peromingo
Carmen Caballero
Teresa Muñoz-Malo
Juan J. Villafruela
Francisco Arrieta
Isabel Zamarrón
Clotilde Vázquez
Publikationsdatum
01.04.2010
Verlag
Springer-Verlag
Erschienen in
Obesity Surgery / Ausgabe 4/2010
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-009-0028-z

Weitere Artikel der Ausgabe 4/2010

Obesity Surgery 4/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.